Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01851447|
Recruitment Status : Active, not recruiting
First Posted : May 10, 2013
Last Update Posted : October 9, 2020
- Some kinds of muscular dystrophy affect the skeletal muscle membrane. In these conditions, the muscle membrane is more fragile. This affects how the muscles contract and relax, which causes movement problems. Researchers are looking at several muscle enzymes, or chemicals that affect how muscle cells function. By studying changes in these enzymes, they may be able to better understand how muscular dystrophy affects the cells. Researchers want to collect biomarkers (chemicals from blood samples) from people with fragile sarcolemmal muscular dystrophy. This information may provide better treatments for this condition.
- To study biomarkers that may affect the muscles of people with fragile sarcolemmal muscular dystrophy.
- Individuals at least 18 years of age with fragile sarcolemmal muscular dystrophy.
- Participants will be screened with a medical history and physical exam.
- Participants will be asked to come for four visits to the National Institutes of Health Clinical Center. The visits will be at least 2 months apart. Each visit will require participants to stay for 5 days at the clinical center.
- During each visit, participants will provide frequent small blood samples. These samples will be collected while at rest and after physical exercise.
- Participants will also have a physical therapy assessment. They will perform standard motor function tests and imaging tests (MRI, MRS). These tests may take up to 1 hour each time.
- Treatment will not be provided as part of this study.
|Condition or disease|
Objectives: the aim of this protocol is to identify biomarker and clinical correlates of changes in the barrier function of skeletal muscle membrane (i.e. cell membrane permeability) before and after routine motor function testing in patients with one of the Fragile Sarcolemmal Muscular Dystrophies (FSMD).
Study population: patients with early adulthood or later onset of a FSMD (LGMD2B-F, I, L, MM, BMD, and MMD3).
Design: pilot study.
Outcome measures: increased change in baseline levels of proteins that are released into the blood from damaged skeletal muscle, such as creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), troponins, and myoglobin in serum, changes in inflammation markers, circulating microRNAs and imaging studies to identify effective biomarkers for use in future clinical trials.
|Study Type :||Observational|
|Actual Enrollment :||11 participants|
|Official Title:||Pilot Study to Assess Biomarkers of Changes in Barrier Function of Skeletal Muscle in Patients With a Fragile Sarcolemmal Muscular Dystrophy|
|Study Start Date :||May 9, 2013|
|Estimated Primary Completion Date :||February 20, 2021|
|Estimated Study Completion Date :||February 20, 2021|
Fragile Sarcolemmal Muscular Dystrophy
patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
- changes in biomarker levels [ Time Frame: early in the morning, before and after morning activities ]biomarker levels (CK, ALT, AST...) increases
- changes in biomarker levels [ Time Frame: after physical exercise, strength test under guidance of physical therapist ]biomarker levels (CK, ALT, AST...) increase
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01851447
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Joshua J Zimmerberg, M.D.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|